Clifford Chance
Clifford Chance advises on Sipai Health Technology Hong Kong IPO and Listing
23 December 2022
Clifford Chance advises on Sipai Health Technology Hong Kong IPO and Listing
Leading international law firm Clifford Chance has advised the joint sponsors Morgan Stanley and Haitong International on Sipai Health Technology Co., Ltd.'s (also known as Medbanks) initial public offering and listing on the mainboard of the Hong Kong Stock Exchange. Sipai Health currently runs three highly synergistic business lines, specialty pharmacy business, physician research assistance and health insurance services, building an integrated health management network that connects the stakeholders and aspires to lead to digital transformation of the healthcare industry in China.
Partners Fang Liu and Christine Xu co-led the deal and supported by consultant Queenie Tong, senior associate Qingyu Wu and associates Jason Ng, Chloe Lau and Ashley Sun.
Fang comments: "We are glad to assist on Sipai's debut on the capital markets against the backdrop of accelerated digital transformation of China's healthcare services during the pandemic."
Clifford Chance regularly advises on many of Hong Kong’s most significant digital healthcare IPOs, including Ping An Good Doctor, Medlive Tech and Dingdang Pharma.
高伟绅助力思派健康科技首次公开发行及香港联交所上市
国际领先律师事务所高伟绅助力思派健康科技有限公司首次公开发行及香港联交所主板上市，担任联席保荐人摩根士丹利和海通国际的法律顾问。
思派健康经营特药药房业务、医生研究协助和健康保险服务三条高度协同的业务线，创建了连接中国医疗健康系统各利益相关者的一体化健康管理网络，致力于引领中国医疗健康行业的数字化转型。
高伟绅香港办公室合伙人方刘律师和许文嘉律师共同牵头领导本次交易，唐嘉雯、吴擎宇、吴子轩、刘颖珩和孙沛遥提供支持。
方律师表示：随着中国医疗服务业的数字化转型在疫情期间加速发展，我们很高兴协助头部企业思派完成资本市场首秀。
高伟绅大中华区上市业务团队长期为香港多个重大的互联网医疗行业的上市项目提供法律服务，包括平安好医生、医脉通、叮当健康。
